Global Meningitis Diagnosis and Treatment Market By Type (Bacterial meningitis, Viral meningitis, Chronic meningitis, Acute meningitis, Fungal meningitis, Parasitic meningitis, Primary Amebic Meningitis (PAM), Others); By Age Group (Newborns, Infants, Adults); By Diagnosis (Blood cultures tests, ELISA Tests, Lateral Flow Assay, PCR Assay, At home tests, Spinal tap, Imaging, Others); By Route of Administration (Oral, Intravenous, Subcutaneous); By Treatment (Vaccines, Medications – Antibiotics, Antifungals, Corticosteroids, Antivirals, IV fluids, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1383 | Category : Healthcare | Published Date : January, 2023 | Pages : 402 | Format :PDF

Industry Trends

Global meningitis diagnosis and treatment market is growing at an estimated CAGR of 3.9% over the forecast period. The human body can be attacked by any disease at any point of time, specifically in the case of the infants. One such disease that has been haunting the mankind is meningitis. Meningitis happens to be an infection that causes inflammation of the fluid and membranes around the brain and spinal cord. This disease is primarily caused by a viral infection though it can also be caused through an infection that is bacterial or fungal. Main symptoms of the meningitis is headache, fever along with stiffness in the neck. Though some forms of this disease can be prevented with the help of the vaccines. As this disease might get dreadful if not treated, and this is the reason why the global meningitis diagnosis and treatment market is growing aggressively.

The global meningitis diagnosis and treatment market flourished during the period of the COVID-19 pandemic. Higher chances of getting contracted with this viral infection gave impetus to this market’s growth.

By Type

On the basis of the type, the global meningitis diagnosis and treatment market has been bifurcated into bacterial meningitis, viral meningitis, chronic meningitis, acute meningitis, fungal meningitis, parasitic meningitis, primary amoebic meningitis (PAM), and others. The bacterial meningitis segment accounts for majority revenue generated by this market. This is due to rising prevalence of this infection in the infants and newborns.

By Age Group

On the basis of age, the global meningitis diagnosis and treatment market has been divided into newborns, infants and others. Newborns are more prone to be infected with any type of infection whether it viral or bacterial, and this is the reason why this segment mints most of the money for this market.

Global Meningitis Diagnosis and Treatment Market   Revenue & Forecast, (US$ Million), 2022 – 2030

Global Meningitis Diagnosis and Treatment Market

By Diagnosis

On the basis of diagnosis, the global meningitis diagnosis and treatment market has been segmented into blood cultures tests, ELISA tests, lateral flow assay, PCR assay, At home tests, spinal tap, imaging, and others. The PCR segment makes most of the money for this market due to effectiveness of this test in diagnosis any type of infection irrespective of what is causing it, virus or bacteria.

By Route of Administration

On the basis of route of administration, the global meningitis diagnosis and treatment market has been segmented into oral, intravenous and subcutaneous. While oral introduction of medicines is extremely easy and convenient, intravenous route of administration is utterly effective, which is why it is being used the most.

By Treatment

The treatment segment of the global meningitis diagnosis and treatment market has been divided into vaccines, medications and others. The medications segment is further bifurcated into antibiotics, antifungals, corticosteroids, antivirals and IV fluids. This segment has been dominating in terms of market share because of its efficacy in curing this life-threatening disease.

By Region

On the basis of region, the global meningitis diagnosis and treatment market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America has been accumulating majority of money for this market. Most advanced healthcare infrastructure in the countries like the United States and Canada contributes the most to the growth of this market.

Competitive Landscape

The report provides both, qualitative and quantitative research of global meningitis diagnosis and treatment market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the major players operating in the global meningitis diagnosis and treatment market are listed below:

  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • ELITechGroup
  • Hoffman-La Roche Ltd
  • Fresensius Kabi India Pvt. Ltd
  • GSK plc
  • Pfizer Inc
  • Sanofi
  • Seegene Inc.
  • Serum Institute of India Pvt. Ltd
  • Thermo Fisher Scientific Inc.
  • Xellia Pharmaceuticals
  • Other Market Participants

Global Meningitis Diagnosis and Treatment Market

By Type

  • Bacterial meningitis
  • Viral meningitis
  • Chronic meningitis
  • Acute meningitis
  • Fungal meningitis
  • Parasitic meningitis
  • Primary Amebic Meningitis (PAM)
  • Others

By Age Group

  • Newborns
  • Infants
  • Adults

By Diagnosis

  • Blood cultures tests
  • ELISA Tests
  • Lateral Flow Assay
  • PCR Assay
  • At home tests
  • Spinal tap
  • Imaging
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

By Treatment

  • Vaccines
  • Medications
    • Antibiotics
    • Antifungals
    • Corticosteroids
    • Antivirals
    • IV fluids
    • Others
  • Others

By Region

  • North America
    • S
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America 


Table of Contents

1.    Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2020

1.2.2. Base Year: 2021

1.2.3. Forecast Years: 2022 - 2030

2.    Key Target Audiences

3.    Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Meningitis Diagnosis and Treatment Market

6.    Market Synopsis:  Meningitis Diagnosis and Treatment Market

7.    Meningitis Diagnosis and Treatment Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Meningitis Diagnosis and Treatment Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Meningitis Diagnosis and Treatment Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on Meningitis Diagnosis and Treatment Market

8.    Global Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

8.1. Overview

8.1.1. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

8.2. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

8.2.1. Bacterial meningitis

8.2.1.1.    Definition

8.2.1.2.    Market Estimation and Penetration, 2015 - 2021

8.2.1.3.    Market Forecast, 2022 - 2030

8.2.1.4.    Compound Annual Growth Rate (CAGR)

8.2.1.5.    Regional Bifurcation

8.2.1.5.1.    North America

8.2.1.5.1.1. Market Estimation, 2015 - 2021

8.2.1.5.1.2. Market Forecast, 2022 - 2030

8.2.1.5.2.    Europe

8.2.1.5.2.1. Market Estimation, 2015 - 2021

8.2.1.5.2.2. Market Forecast, 2022 - 2030

8.2.1.5.3.    Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 - 2021

8.2.1.5.3.2. Market Forecast, 2022 - 2030

8.2.1.5.4.    Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 - 2021

8.2.1.5.4.2. Market Forecast, 2022 - 2030

8.2.1.5.5.    Latin America

8.2.1.5.5.1. Market Estimation, 2015 - 2021

8.2.1.5.5.2. Market Forecast, 2022 - 2030

8.2.2. Viral meningitis

8.2.2.1.    Definition

8.2.2.2.    Market Estimation and Penetration, 2015 - 2021

8.2.2.3.    Market Forecast, 2022 - 2030

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.2.5.    Regional Bifurcation

8.2.2.5.1.    North America

8.2.2.5.1.1. Market Estimation, 2015 - 2021

8.2.2.5.1.2. Market Forecast, 2022 - 2030

8.2.2.5.2.    Europe

8.2.2.5.2.1. Market Estimation, 2015 - 2021

8.2.2.5.2.2. Market Forecast, 2022 - 2030

8.2.2.5.3.    Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 - 2021

8.2.2.5.3.2. Market Forecast, 2022 - 2030

8.2.2.5.4.    Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 - 2021

8.2.2.5.4.2. Market Forecast, 2022 - 2030

8.2.2.5.5.    Latin America

8.2.2.5.5.1. Market Estimation, 2015 - 2021

8.2.2.5.5.2. Market Forecast, 2022 - 2030

8.2.3. Chronic meningitis

8.2.3.1.    Definition

8.2.3.2.    Market Estimation and Penetration, 2015 - 2021

8.2.3.3.    Market Forecast, 2022 - 2030

8.2.3.4.    Compound Annual Growth Rate (CAGR)

8.2.3.5.    Regional Bifurcation

8.2.3.5.1.    North America

8.2.3.5.1.1. Market Estimation, 2015 - 2021

8.2.3.5.1.2. Market Forecast, 2022 - 2030

8.2.3.5.2.    Europe

8.2.3.5.2.1. Market Estimation, 2015 - 2021

8.2.3.5.2.2. Market Forecast, 2022 - 2030

8.2.3.5.3.    Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 - 2021

8.2.3.5.3.2. Market Forecast, 2022 - 2030

8.2.3.5.4.    Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 - 2021

8.2.3.5.4.2. Market Forecast, 2022 - 2030

8.2.3.5.5.    Latin America

8.2.3.5.5.1. Market Estimation, 2015 - 2021

8.2.3.5.5.2. Market Forecast, 2022 - 2030

8.2.4. Acute meningitis

8.2.4.1.    Definition

8.2.4.2.    Market Estimation and Penetration, 2015 - 2021

8.2.4.3.    Market Forecast, 2022 - 2030

8.2.4.4.    Compound Annual Growth Rate (CAGR)

8.2.4.5.    Regional Bifurcation

8.2.4.5.1.    North America

8.2.4.5.1.1. Market Estimation, 2015 - 2021

8.2.4.5.1.2. Market Forecast, 2022 - 2030

8.2.4.5.2.    Europe

8.2.4.5.2.1. Market Estimation, 2015 - 2021

8.2.4.5.2.2. Market Forecast, 2022 - 2030

8.2.4.5.3.    Asia Pacific

8.2.4.5.3.1. Market Estimation, 2015 - 2021

8.2.4.5.3.2. Market Forecast, 2022 - 2030

8.2.4.5.4.    Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2015 - 2021

8.2.4.5.4.2. Market Forecast, 2022 - 2030

8.2.4.5.5.    Latin America

8.2.4.5.5.1. Market Estimation, 2015 - 2021

8.2.4.5.5.2. Market Forecast, 2022 - 2030

8.2.5. Fungal meningitis

8.2.5.1.    Definition

8.2.5.2.    Market Estimation and Penetration, 2015 - 2021

8.2.5.3.    Market Forecast, 2022 - 2030

8.2.5.4.    Compound Annual Growth Rate (CAGR)

8.2.5.5.    Regional Bifurcation

8.2.5.5.1.    North America

8.2.5.5.1.1. Market Estimation, 2015 - 2021

8.2.5.5.1.2. Market Forecast, 2022 - 2030

8.2.5.5.2.    Europe

8.2.5.5.2.1. Market Estimation, 2015 - 2021

8.2.5.5.2.2. Market Forecast, 2022 - 2030

8.2.5.5.3.    Asia Pacific

8.2.5.5.3.1. Market Estimation, 2015 - 2021

8.2.5.5.3.2. Market Forecast, 2022 - 2030

8.2.5.5.4.    Middle East and Africa

8.2.5.5.4.1. Market Estimation, 2015 - 2021

8.2.5.5.4.2. Market Forecast, 2022 - 2030

8.2.5.5.5.    Latin America

8.2.5.5.5.1. Market Estimation, 2015 - 2021

8.2.5.5.5.2. Market Forecast, 2022 - 2030

8.2.6. Parasitic meningitis

8.2.6.1.    Definition

8.2.6.2.    Market Estimation and Penetration, 2015 - 2021

8.2.6.3.    Market Forecast, 2022 - 2030

8.2.6.4.    Compound Annual Growth Rate (CAGR)

8.2.6.5.    Regional Bifurcation

8.2.6.5.1.    North America

8.2.6.5.1.1. Market Estimation, 2015 - 2021

8.2.6.5.1.2. Market Forecast, 2022 - 2030

8.2.6.5.2.    Europe

8.2.6.5.2.1. Market Estimation, 2015 - 2021

8.2.6.5.2.2. Market Forecast, 2022 - 2030

8.2.6.5.3.    Asia Pacific

8.2.6.5.3.1. Market Estimation, 2015 - 2021

8.2.6.5.3.2. Market Forecast, 2022 - 2030

8.2.6.5.4.    Middle East and Africa

8.2.6.5.4.1. Market Estimation, 2015 - 2021

8.2.6.5.4.2. Market Forecast, 2022 - 2030

8.2.6.5.5.    Latin America

8.2.6.5.5.1. Market Estimation, 2015 - 2021

8.2.6.5.5.2. Market Forecast, 2022 - 2030

8.2.7. Primary Amebic Meningitis (PAM)

8.2.7.1.    Definition

8.2.7.2.    Market Estimation and Penetration, 2015 - 2021

8.2.7.3.    Market Forecast, 2022 - 2030

8.2.7.4.    Compound Annual Growth Rate (CAGR)

8.2.7.5.    Regional Bifurcation

8.2.7.5.1.    North America

8.2.7.5.1.1. Market Estimation, 2015 - 2021

8.2.7.5.1.2. Market Forecast, 2022 - 2030

8.2.7.5.2.    Europe

8.2.7.5.2.1. Market Estimation, 2015 - 2021

8.2.7.5.2.2. Market Forecast, 2022 - 2030

8.2.7.5.3.    Asia Pacific

8.2.7.5.3.1. Market Estimation, 2015 - 2021

8.2.7.5.3.2. Market Forecast, 2022 - 2030

8.2.7.5.4.    Middle East and Africa

8.2.7.5.4.1. Market Estimation, 2015 - 2021

8.2.7.5.4.2. Market Forecast, 2022 - 2030

8.2.7.5.5.    Latin America

8.2.7.5.5.1. Market Estimation, 2015 - 2021

8.2.7.5.5.2. Market Forecast, 2022 - 2030

8.2.8. Others

8.2.8.1.    Definition

8.2.8.2.    Market Estimation and Penetration, 2015 - 2021

8.2.8.3.    Market Forecast, 2022 - 2030

8.2.8.4.    Compound Annual Growth Rate (CAGR)

8.2.8.5.    Regional Bifurcation

8.2.8.5.1.    North America

8.2.8.5.1.1. Market Estimation, 2015 - 2021

8.2.8.5.1.2. Market Forecast, 2022 - 2030

8.2.8.5.2.    Europe

8.2.8.5.2.1. Market Estimation, 2015 - 2021

8.2.8.5.2.2. Market Forecast, 2022 - 2030

8.2.8.5.3.    Asia Pacific

8.2.8.5.3.1. Market Estimation, 2015 - 2021

8.2.8.5.3.2. Market Forecast, 2022 - 2030

8.2.8.5.4.    Middle East and Africa

8.2.8.5.4.1. Market Estimation, 2015 - 2021

8.2.8.5.4.2. Market Forecast, 2022 - 2030

8.2.8.5.5.    Latin America

8.2.8.5.5.1. Market Estimation, 2015 - 2021

8.2.8.5.5.2. Market Forecast, 2022 - 2030

8.3. Key Segment for Channeling Investments

8.3.1. By Type

9.    Global Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

9.1. Overview

9.2. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

9.2.1. Newborns

9.2.1.1.    Definition

9.2.1.2.    Market Estimation and Penetration, 2015 - 2021

9.2.1.3.    Market Forecast, 2022 - 2030

9.2.1.4.    Compound Annual Growth Rate (CAGR)

9.2.1.5.    Regional Bifurcation

9.2.1.5.1.    North America

9.2.1.5.1.1. Market Estimation, 2015 - 2021

9.2.1.5.1.2. Market Forecast, 2022 - 2030

9.2.1.5.2.    Europe

9.2.1.5.2.1. Market Estimation, 2015 - 2021

9.2.1.5.2.2. Market Forecast, 2022 - 2030

9.2.1.5.3.    Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 - 2021

9.2.1.5.3.2. Market Forecast, 2022 - 2030

9.2.1.5.4.    Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 - 2021

9.2.1.5.4.2. Market Forecast, 2022 - 2030

9.2.1.5.5.    Latin America

9.2.1.5.5.1. Market Estimation, 2015 - 2021

9.2.1.5.5.2. Market Forecast, 2022 - 2030

9.2.2. Infants

9.2.2.1.    Definition

9.2.2.2.    Market Estimation and Penetration, 2015 - 2021

9.2.2.3.    Market Forecast, 2022 - 2030

9.2.2.4.    Compound Annual Growth Rate (CAGR)

9.2.2.5.    Regional Bifurcation

9.2.2.5.1.    North America

9.2.2.5.1.1. Market Estimation, 2015 - 2021

9.2.2.5.1.2. Market Forecast, 2022 - 2030

9.2.2.5.2.    Europe

9.2.2.5.2.1. Market Estimation, 2015 - 2021

9.2.2.5.2.2. Market Forecast, 2022 - 2030

9.2.2.5.3.    Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 - 2021

9.2.2.5.3.2. Market Forecast, 2022 - 2030

9.2.2.5.4.    Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 - 2021

9.2.2.5.4.2. Market Forecast, 2022 - 2030

9.2.2.5.5.    Latin America

9.2.2.5.5.1. Market Estimation, 2015 - 2021

9.2.2.5.5.2. Market Forecast, 2022 - 2030

9.2.3. Adults

9.2.3.1.    Definition

9.2.3.2.    Market Estimation and Penetration, 2015 - 2021

9.2.3.3.    Market Forecast, 2022 - 2030

9.2.3.4.    Compound Annual Growth Rate (CAGR)

9.2.3.5.    Regional Bifurcation

9.2.3.5.1.    North America

9.2.3.5.1.1. Market Estimation, 2015 - 2021

9.2.3.5.1.2. Market Forecast, 2022 - 2030

9.2.3.5.2.    Europe

9.2.3.5.2.1. Market Estimation, 2015 - 2021

9.2.3.5.2.2. Market Forecast, 2022 - 2030

9.2.3.5.3.    Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 - 2021

9.2.3.5.3.2. Market Forecast, 2022 - 2030

9.2.3.5.4.    Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 - 2021

9.2.3.5.4.2. Market Forecast, 2022 - 2030

9.2.3.5.5.    Latin America

9.2.3.5.5.1. Market Estimation, 2015 - 2021

9.2.3.5.5.2. Market Forecast, 2022 - 2030

9.3. Key Segment for Channeling Investments

9.3.1. By Age Group

10. Global Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

10.1. Overview

10.2. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

10.2.1. Blood cultures tests

10.2.1.1.  Definition

10.2.1.2.  Market Estimation and Penetration, 2015 - 2021

10.2.1.3.  Market Forecast, 2022 - 2030

10.2.1.4.  Compound Annual Growth Rate (CAGR)

10.2.1.5.  Regional Bifurcation

10.2.1.5.1.  North America

10.2.1.5.1.1. Market Estimation, 2015 - 2021

10.2.1.5.1.2. Market Forecast, 2022 - 2030

10.2.1.5.2.  Europe

10.2.1.5.2.1. Market Estimation, 2015 - 2021

10.2.1.5.2.2. Market Forecast, 2022 - 2030

10.2.1.5.3.  Asia Pacific

10.2.1.5.3.1. Market Estimation, 2015 - 2021

10.2.1.5.3.2. Market Forecast, 2022 - 2030

10.2.1.5.4.  Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2015 - 2021

10.2.1.5.4.2. Market Forecast, 2022 - 2030

10.2.1.5.5.  Latin America

10.2.1.5.5.1. Market Estimation, 2015 - 2021

10.2.1.5.5.2. Market Forecast, 2022 - 2030

10.2.2. ELISA Tests

10.2.2.1.  Definition

10.2.2.2.  Market Estimation and Penetration, 2015 - 2021

10.2.2.3.  Market Forecast, 2022 - 2030

10.2.2.4.  Compound Annual Growth Rate (CAGR)

10.2.2.5.  Regional Bifurcation

10.2.2.5.1.  North America

10.2.2.5.1.1. Market Estimation, 2015 - 2021

10.2.2.5.1.2. Market Forecast, 2022 - 2030

10.2.2.5.2.  Europe

10.2.2.5.2.1. Market Estimation, 2015 - 2021

10.2.2.5.2.2. Market Forecast, 2022 - 2030

10.2.2.5.3.  Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 - 2021

10.2.2.5.3.2. Market Forecast, 2022 - 2030

10.2.2.5.4.  Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 - 2021

10.2.2.5.4.2. Market Forecast, 2022 - 2030

10.2.2.5.5.  Latin America

10.2.2.5.5.1. Market Estimation, 2015 - 2021

10.2.2.5.5.2. Market Forecast, 2022 - 2030

10.2.3. Lateral Flow Assay

10.2.3.1.  Definition

10.2.3.2.  Market Estimation and Penetration, 2015 - 2021

10.2.3.3.  Market Forecast, 2022 - 2030

10.2.3.4.  Compound Annual Growth Rate (CAGR)

10.2.3.5.  Regional Bifurcation

10.2.3.5.1.  North America

10.2.3.5.1.1. Market Estimation, 2015 - 2021

10.2.3.5.1.2. Market Forecast, 2022 - 2030

10.2.3.5.2.  Europe

10.2.3.5.2.1. Market Estimation, 2015 - 2021

10.2.3.5.2.2. Market Forecast, 2022 - 2030

10.2.3.5.3.  Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 - 2021

10.2.3.5.3.2. Market Forecast, 2022 - 2030

10.2.3.5.4.  Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 - 2021

10.2.3.5.4.2. Market Forecast, 2022 - 2030

10.2.3.5.5.  Latin America

10.2.3.5.5.1. Market Estimation, 2015 - 2021

10.2.3.5.5.2. Market Forecast, 2022 - 2030

10.2.4. PCR Assay

10.2.4.1.  Definition

10.2.4.2.  Market Estimation and Penetration, 2015 - 2021

10.2.4.3.  Market Forecast, 2022 - 2030

10.2.4.4.  Compound Annual Growth Rate (CAGR)

10.2.4.5.  Regional Bifurcation

10.2.4.5.1.  North America

10.2.4.5.1.1. Market Estimation, 2015 - 2021

10.2.4.5.1.2. Market Forecast, 2022 - 2030

10.2.4.5.2.  Europe

10.2.4.5.2.1. Market Estimation, 2015 - 2021

10.2.4.5.2.2. Market Forecast, 2022 - 2030

10.2.4.5.3.  Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 - 2021

10.2.4.5.3.2. Market Forecast, 2022 - 2030

10.2.4.5.4.  Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 - 2021

10.2.4.5.4.2. Market Forecast, 2022 - 2030

10.2.4.5.5.  Latin America

10.2.4.5.5.1. Market Estimation, 2015 - 2021

10.2.4.5.5.2. Market Forecast, 2022 - 2030

10.2.5. At home tests

10.2.5.1.  Definition

10.2.5.2.  Market Estimation and Penetration, 2015 - 2021

10.2.5.3.  Market Forecast, 2022 - 2030

10.2.5.4.  Compound Annual Growth Rate (CAGR)

10.2.5.5.  Regional Bifurcation

10.2.5.5.1.  North America

10.2.5.5.1.1. Market Estimation, 2015 - 2021

10.2.5.5.1.2. Market Forecast, 2022 - 2030

10.2.5.5.2.  Europe

10.2.5.5.2.1. Market Estimation, 2015 - 2021

10.2.5.5.2.2. Market Forecast, 2022 - 2030

10.2.5.5.3.  Asia Pacific

10.2.5.5.3.1. Market Estimation, 2015 - 2021

10.2.5.5.3.2. Market Forecast, 2022 - 2030

10.2.5.5.4.  Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2015 - 2021

10.2.5.5.4.2. Market Forecast, 2022 - 2030

10.2.5.5.5.  Latin America

10.2.5.5.5.1. Market Estimation, 2015 - 2021

10.2.5.5.5.2. Market Forecast, 2022 - 2030

10.2.6. Spinal tap

10.2.6.1.  Definition

10.2.6.2.  Market Estimation and Penetration, 2015 - 2021

10.2.6.3.  Market Forecast, 2022 - 2030

10.2.6.4.  Compound Annual Growth Rate (CAGR)

10.2.6.5.  Regional Bifurcation

10.2.6.5.1.  North America

10.2.6.5.1.1. Market Estimation, 2015 - 2021

10.2.6.5.1.2. Market Forecast, 2022 - 2030

10.2.6.5.2.  Europe

10.2.6.5.2.1. Market Estimation, 2015 - 2021

10.2.6.5.2.2. Market Forecast, 2022 - 2030

10.2.6.5.3.  Asia Pacific

10.2.6.5.3.1. Market Estimation, 2015 - 2021

10.2.6.5.3.2. Market Forecast, 2022 - 2030

10.2.6.5.4.  Middle East and Africa

10.2.6.5.4.1. Market Estimation, 2015 - 2021

10.2.6.5.4.2. Market Forecast, 2022 - 2030

10.2.6.5.5.  Latin America

10.2.6.5.5.1. Market Estimation, 2015 - 2021

10.2.6.5.5.2. Market Forecast, 2022 - 2030

10.2.7. Imaging

10.2.7.1.  Definition

10.2.7.2.  Market Estimation and Penetration, 2015 - 2021

10.2.7.3.  Market Forecast, 2022 - 2030

10.2.7.4.  Compound Annual Growth Rate (CAGR)

10.2.7.5.  Regional Bifurcation

10.2.7.5.1.  North America

10.2.7.5.1.1. Market Estimation, 2015 - 2021

10.2.7.5.1.2. Market Forecast, 2022 - 2030

10.2.7.5.2.  Europe

10.2.7.5.2.1. Market Estimation, 2015 - 2021

10.2.7.5.2.2. Market Forecast, 2022 - 2030

10.2.7.5.3.  Asia Pacific

10.2.7.5.3.1. Market Estimation, 2015 - 2021

10.2.7.5.3.2. Market Forecast, 2022 - 2030

10.2.7.5.4.  Middle East and Africa

10.2.7.5.4.1. Market Estimation, 2015 - 2021

10.2.7.5.4.2. Market Forecast, 2022 - 2030

10.2.7.5.5.  Latin America

10.2.7.5.5.1. Market Estimation, 2015 - 2021

10.2.7.5.5.2. Market Forecast, 2022 - 2030

10.2.8. Others

10.2.8.1.  Definition

10.2.8.2.  Market Estimation and Penetration, 2015 - 2021

10.2.8.3.  Market Forecast, 2022 - 2030

10.2.8.4.  Compound Annual Growth Rate (CAGR)

10.2.8.5.  Regional Bifurcation

10.2.8.5.1.  North America

10.2.8.5.1.1. Market Estimation, 2015 - 2021

10.2.8.5.1.2. Market Forecast, 2022 - 2030

10.2.8.5.2.  Europe

10.2.8.5.2.1. Market Estimation, 2015 - 2021

10.2.8.5.2.2. Market Forecast, 2022 - 2030

10.2.8.5.3.  Asia Pacific

10.2.8.5.3.1. Market Estimation, 2015 - 2021

10.2.8.5.3.2. Market Forecast, 2022 - 2030

10.2.8.5.4.  Middle East and Africa

10.2.8.5.4.1. Market Estimation, 2015 - 2021

10.2.8.5.4.2. Market Forecast, 2022 - 2030

10.2.8.5.5.  Latin America

10.2.8.5.5.1. Market Estimation, 2015 - 2021

10.2.8.5.5.2. Market Forecast, 2022 - 2030

10.3. Key Segment for Channeling Investments

10.3.1. By Diagnosis Type

11. Global Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

11.1. Overview

11.2. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

11.2.1. Oral

11.2.1.1.  Definition

11.2.1.2.  Market Estimation and Penetration, 2015 - 2021

11.2.1.3.  Market Forecast, 2022 - 2030

11.2.1.4.  Compound Annual Growth Rate (CAGR)

11.2.1.5.  Regional Bifurcation

11.2.1.5.1.  North America

11.2.1.5.1.1. Market Estimation, 2015 - 2021

11.2.1.5.1.2. Market Forecast, 2022 - 2030

11.2.1.5.2.  Europe

11.2.1.5.2.1. Market Estimation, 2015 - 2021

11.2.1.5.2.2. Market Forecast, 2022 - 2030

11.2.1.5.3.  Asia Pacific

11.2.1.5.3.1. Market Estimation, 2015 - 2021

11.2.1.5.3.2. Market Forecast, 2022 - 2030

11.2.1.5.4.  Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2015 - 2021

11.2.1.5.4.2. Market Forecast, 2022 - 2030

11.2.1.5.5.  Latin America

11.2.1.5.5.1. Market Estimation, 2015 - 2021

11.2.1.5.5.2. Market Forecast, 2022 - 2030

11.2.2. Intravenous

11.2.2.1.  Definition

11.2.2.2.  Market Estimation and Penetration, 2015 - 2021

11.2.2.3.  Market Forecast, 2022 - 2030

11.2.2.4.  Compound Annual Growth Rate (CAGR)

11.2.2.5.  Regional Bifurcation

11.2.2.5.1.  North America

11.2.2.5.1.1. Market Estimation, 2015 - 2021

11.2.2.5.1.2. Market Forecast, 2022 - 2030

11.2.2.5.2.  Europe

11.2.2.5.2.1. Market Estimation, 2015 - 2021

11.2.2.5.2.2. Market Forecast, 2022 - 2030

11.2.2.5.3.  Asia Pacific

11.2.2.5.3.1. Market Estimation, 2015 - 2021

11.2.2.5.3.2. Market Forecast, 2022 - 2030

11.2.2.5.4.  Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2015 - 2021

11.2.2.5.4.2. Market Forecast, 2022 - 2030

11.2.2.5.5.  Latin America

11.2.2.5.5.1. Market Estimation, 2015 - 2021

11.2.2.5.5.2. Market Forecast, 2022 - 2030

11.2.3. Subcutaneous

11.2.3.1.  Definition

11.2.3.2.  Market Estimation and Penetration, 2015 - 2021

11.2.3.3.  Market Forecast, 2022 - 2030

11.2.3.4.  Compound Annual Growth Rate (CAGR)

11.2.3.5.  Regional Bifurcation

11.2.3.5.1.  North America

11.2.3.5.1.1. Market Estimation, 2015 - 2021

11.2.3.5.1.2. Market Forecast, 2022 - 2030

11.2.3.5.2.  Europe

11.2.3.5.2.1. Market Estimation, 2015 - 2021

11.2.3.5.2.2. Market Forecast, 2022 - 2030

11.2.3.5.3.  Asia Pacific

11.2.3.5.3.1. Market Estimation, 2015 - 2021

11.2.3.5.3.2. Market Forecast, 2022 - 2030

11.2.3.5.4.  Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2015 - 2021

11.2.3.5.4.2. Market Forecast, 2022 - 2030

11.2.3.5.5.  Latin America

11.2.3.5.5.1. Market Estimation, 2015 - 2021

11.2.3.5.5.2. Market Forecast, 2022 - 2030

11.3. Key Segment for Channeling Investments

11.3.1. By Route of Administration

12. Global Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.2. Global Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

12.2.1. Vaccines

12.2.1.1.  Definition

12.2.1.2.  Market Estimation and Penetration, 2015 - 2021

12.2.1.3.  Market Forecast, 2022 - 2030

12.2.1.4.  Compound Annual Growth Rate (CAGR)

12.2.1.5.  Regional Bifurcation

12.2.1.5.1.  North America

12.2.1.5.1.1. Market Estimation, 2015 - 2021

12.2.1.5.1.2. Market Forecast, 2022 - 2030

12.2.1.5.2.  Europe

12.2.1.5.2.1. Market Estimation, 2015 - 2021

12.2.1.5.2.2. Market Forecast, 2022 - 2030

12.2.1.5.3.  Asia Pacific

12.2.1.5.3.1. Market Estimation, 2015 - 2021

12.2.1.5.3.2. Market Forecast, 2022 - 2030

12.2.1.5.4.  Middle East and Africa

12.2.1.5.4.1. Market Estimation, 2015 - 2021

12.2.1.5.4.2. Market Forecast, 2022 - 2030

12.2.1.5.5.  Latin America

12.2.1.5.5.1. Market Estimation, 2015 - 2021

12.2.1.5.5.2. Market Forecast, 2022 - 2030

12.2.2. Medications (Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Antibiotics, Antifungals, Corticosteroids, Antivirals, IV fluids, Others)

12.2.2.1.  Antibiotics

12.2.2.2.  Antifungals

12.2.2.3.  Corticosteroids

12.2.2.4.  Antivirals

12.2.2.5.  IV fluids

12.2.2.6.  Others

12.2.3. Others

12.2.3.1.  Definition

12.2.3.2.  Market Estimation and Penetration, 2015 - 2021

12.2.3.3.  Market Forecast, 2022 - 2030

12.2.3.4.  Compound Annual Growth Rate (CAGR)

12.2.3.5.  Regional Bifurcation

12.2.3.5.1.  North America

12.2.3.5.1.1. Market Estimation, 2015 - 2021

12.2.3.5.1.2. Market Forecast, 2022 - 2030

12.2.3.5.2.  Europe

12.2.3.5.2.1. Market Estimation, 2015 - 2021

12.2.3.5.2.2. Market Forecast, 2022 - 2030

12.2.3.5.3.  Asia Pacific

12.2.3.5.3.1. Market Estimation, 2015 - 2021

12.2.3.5.3.2. Market Forecast, 2022 - 2030

12.2.3.5.4.  Middle East and Africa

12.2.3.5.4.1. Market Estimation, 2015 - 2021

12.2.3.5.4.2. Market Forecast, 2022 - 2030

12.2.3.5.5.  Latin America

12.2.3.5.5.1. Market Estimation, 2015 - 2021

12.2.3.5.5.2. Market Forecast, 2022 - 2030

12.3. Key Segment for Channeling Investments

12.3.1. By Treatment Type

13. North America Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

13.2. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

13.2.1. Bacterial meningitis

13.2.2. Viral meningitis

13.2.3. Chronic meningitis

13.2.4. Acute meningitis

13.2.5. Fungal meningitis

13.2.6. Parasitic meningitis

13.2.7. Primary Amebic Meningitis (PAM)

13.2.8. Others

13.3. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

13.3.1. Newborns

13.3.2. Infants

13.3.3. Adults

13.4. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

13.4.1. Blood cultures tests

13.4.2. ELISA Tests

13.4.3. Lateral Flow Assay

13.4.4. PCR Assay

13.4.5. At home tests

13.4.6. Spinal tap

13.4.7. Imaging

13.4.8. Others

13.5. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.5.1. Oral

13.5.2. Intravenous

13.5.3. Subcutaneous

13.6. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

13.6.1. Vaccines

13.6.2. Medications

13.6.2.1.  Antibiotics

13.6.2.2.  Antifungals

13.6.2.3.  Corticosteroids

13.6.2.4.  Antivirals

13.6.2.5.  IV fluids

13.6.2.6.  Others

13.6.3. Others

13.7. North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

13.7.1. U.S

13.7.1.1.  U.S Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

13.7.1.1.1.  Bacterial meningitis

13.7.1.1.2.  Viral meningitis

13.7.1.1.3.  Chronic meningitis

13.7.1.1.4.  Acute meningitis

13.7.1.1.5.  Fungal meningitis

13.7.1.1.6.  Parasitic meningitis

13.7.1.1.7.  Primary Amebic Meningitis (PAM)

13.7.1.1.8.  Others

13.7.1.2.  U.S Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

13.7.1.2.1.  Newborns

13.7.1.2.2.  Infants

13.7.1.2.3.  Adults

13.7.1.3.  U.S Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

13.7.1.3.1.  Blood cultures tests

13.7.1.3.2.  ELISA Tests

13.7.1.3.3.  Lateral Flow Assay

13.7.1.3.4.  PCR Assay

13.7.1.3.5.  At home tests

13.7.1.3.6.  Spinal tap

13.7.1.3.7.  Imaging

13.7.1.3.8.  Others

13.7.1.4.  U.S Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.7.1.4.1.  Oral

13.7.1.4.2.  Intravenous

13.7.1.4.3.  Subcutaneous

13.7.1.5.  U.S Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

13.7.1.5.1.  Vaccines

13.7.1.5.2.  Medications

13.7.1.5.2.1. Antibiotics

13.7.1.5.2.2. Antifungals

13.7.1.5.2.3. Corticosteroids

13.7.1.5.2.4. Antivirals

13.7.1.5.2.5. IV fluids

13.7.1.5.2.6. Others

13.7.1.5.3.  Others

13.7.2. Canada

13.7.2.1.  Canada Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

13.7.2.1.1.  Bacterial meningitis

13.7.2.1.2.  Viral meningitis

13.7.2.1.3.  Chronic meningitis

13.7.2.1.4.  Acute meningitis

13.7.2.1.5.  Fungal meningitis

13.7.2.1.6.  Parasitic meningitis

13.7.2.1.7.  Primary Amebic Meningitis (PAM)

13.7.2.1.8.  Others

13.7.2.2.  Canada Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

13.7.2.2.1.  Newborns

13.7.2.2.2.  Infants

13.7.2.2.3.  Adults

13.7.2.3.  Canada Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

13.7.2.3.1.  Blood cultures tests

13.7.2.3.2.  ELISA Tests

13.7.2.3.3.  Lateral Flow Assay

13.7.2.3.4.  PCR Assay

13.7.2.3.5.  At home tests

13.7.2.3.6.  Spinal tap

13.7.2.3.7.  Imaging

13.7.2.3.8.  Others

13.7.2.4.  Canada Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.7.2.4.1.  Oral

13.7.2.4.2.  Intravenous

13.7.2.4.3.  Subcutaneous

13.7.2.5.  Canada Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

13.7.2.5.1.  Vaccines

13.7.2.5.2.  Medications

13.7.2.5.2.1. Antibiotics

13.7.2.5.2.2. Antifungals

13.7.2.5.2.3. Corticosteroids

13.7.2.5.2.4. Antivirals

13.7.2.5.2.5. IV fluids

13.7.2.5.2.6. Others

13.7.2.5.3.  Others

13.7.3. Mexico

13.7.3.1.  Mexico Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

13.7.3.1.1.  Bacterial meningitis

13.7.3.1.2.  Viral meningitis

13.7.3.1.3.  Chronic meningitis

13.7.3.1.4.  Acute meningitis

13.7.3.1.5.  Fungal meningitis

13.7.3.1.6.  Parasitic meningitis

13.7.3.1.7.  Primary Amebic Meningitis (PAM)

13.7.3.1.8.  Others

13.7.3.2.  Mexico Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

13.7.3.2.1.  Newborns

13.7.3.2.2.  Infants

13.7.3.2.3.  Adults

13.7.3.3.  Mexico Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

13.7.3.3.1.  Blood cultures tests

13.7.3.3.2.  ELISA Tests

13.7.3.3.3.  Lateral Flow Assay

13.7.3.3.4.  PCR Assay

13.7.3.3.5.  At home tests

13.7.3.3.6.  Spinal tap

13.7.3.3.7.  Imaging

13.7.3.3.8.  Others

13.7.3.4.  Mexico Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.7.3.4.1.  Oral

13.7.3.4.2.  Intravenous

13.7.3.4.3.  Subcutaneous

13.7.3.5.  Mexico Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

13.7.3.5.1.  Vaccines

13.7.3.5.2.  Medications

13.7.3.5.2.1. Antibiotics

13.7.3.5.2.2. Antifungals

13.7.3.5.2.3. Corticosteroids

13.7.3.5.2.4. Antivirals

13.7.3.5.2.5. IV fluids

13.7.3.5.2.6. Others

13.7.3.5.3.  Others

13.7.4. Rest of North America

13.7.4.1.  Rest of North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

13.7.4.1.1.  Bacterial meningitis

13.7.4.1.2.  Viral meningitis

13.7.4.1.3.  Chronic meningitis

13.7.4.1.4.  Acute meningitis

13.7.4.1.5.  Fungal meningitis

13.7.4.1.6.  Parasitic meningitis

13.7.4.1.7.  Primary Amebic Meningitis (PAM)

13.7.4.1.8.  Others

13.7.4.2.  Rest of North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

13.7.4.2.1.  Newborns

13.7.4.2.2.  Infants

13.7.4.2.3.  Adults

13.7.4.3.  Rest of North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

13.7.4.3.1.  Blood cultures tests

13.7.4.3.2.  ELISA Tests

13.7.4.3.3.  Lateral Flow Assay

13.7.4.3.4.  PCR Assay

13.7.4.3.5.  At home tests

13.7.4.3.6.  Spinal tap

13.7.4.3.7.  Imaging

13.7.4.3.8.  Others

13.7.4.4.  Rest of North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.7.4.4.1.  Oral

13.7.4.4.2.  Intravenous

13.7.4.4.3.  Subcutaneous

13.7.4.5.  Rest of North America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

13.7.4.5.1.  Vaccines

13.7.4.5.2.  Medications

13.7.4.5.2.1. Antibiotics

13.7.4.5.2.2. Antifungals

13.7.4.5.2.3. Corticosteroids

13.7.4.5.2.4. Antivirals

13.7.4.5.2.5. IV fluids

13.7.4.5.2.6. Others

13.7.4.5.3.  Others

13.8. Key Segment for Channeling Investments

13.8.1. By Country

13.8.2. By Type

13.8.3. By Age Group

13.8.4. By Diagnosis Type

13.8.5. By Route of Administration

13.8.6. By Treatment Type

14. Europe Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

14.2. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.2.1. Bacterial meningitis

14.2.2. Viral meningitis

14.2.3. Chronic meningitis

14.2.4. Acute meningitis

14.2.5. Fungal meningitis

14.2.6. Parasitic meningitis

14.2.7. Primary Amebic Meningitis (PAM)

14.2.8. Others

14.3. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.3.1. Newborns

14.3.2. Infants

14.3.3. Adults

14.4. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.4.1. Blood cultures tests

14.4.2. ELISA Tests

14.4.3. Lateral Flow Assay

14.4.4. PCR Assay

14.4.5. At home tests

14.4.6. Spinal tap

14.4.7. Imaging

14.4.8. Others

14.5. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.5.1. Oral

14.5.2. Intravenous

14.5.3. Subcutaneous

14.6. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.6.1. Vaccines

14.6.2. Medications

14.6.2.1.  Antibiotics

14.6.2.2.  Antifungals

14.6.2.3.  Corticosteroids

14.6.2.4.  Antivirals

14.6.2.5.  IV fluids

14.6.2.6.  Others

14.6.3. Others

14.7. Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

14.7.1. France

14.7.1.1.  France Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.1.1.1.  Bacterial meningitis

14.7.1.1.2.  Viral meningitis

14.7.1.1.3.  Chronic meningitis

14.7.1.1.4.  Acute meningitis

14.7.1.1.5.  Fungal meningitis

14.7.1.1.6.  Parasitic meningitis

14.7.1.1.7.  Primary Amebic Meningitis (PAM)

14.7.1.1.8.  Others

14.7.1.2.  France Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.1.2.1.  Newborns

14.7.1.2.2.  Infants

14.7.1.2.3.  Adults

14.7.1.3.  France Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.1.3.1.  Blood cultures tests

14.7.1.3.2.  ELISA Tests

14.7.1.3.3.  Lateral Flow Assay

14.7.1.3.4.  PCR Assay

14.7.1.3.5.  At home tests

14.7.1.3.6.  Spinal tap

14.7.1.3.7.  Imaging

14.7.1.3.8.  Others

14.7.1.4.  France Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.1.4.1.  Oral

14.7.1.4.2.  Intravenous

14.7.1.4.3.  Subcutaneous

14.7.1.5.  France Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.1.5.1.  Vaccines

14.7.1.5.2.  Medications

14.7.1.5.2.1. Antibiotics

14.7.1.5.2.2. Antifungals

14.7.1.5.2.3. Corticosteroids

14.7.1.5.2.4. Antivirals

14.7.1.5.2.5. IV fluids

14.7.1.5.2.6. Others

14.7.1.5.3.  Others

14.7.2. The UK

14.7.2.1.  The UK Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.2.1.1.  Bacterial meningitis

14.7.2.1.2.  Viral meningitis

14.7.2.1.3.  Chronic meningitis

14.7.2.1.4.  Acute meningitis

14.7.2.1.5.  Fungal meningitis

14.7.2.1.6.  Parasitic meningitis

14.7.2.1.7.  Primary Amebic Meningitis (PAM)

14.7.2.1.8.  Others

14.7.2.2.  The UK Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.2.2.1.  Newborns

14.7.2.2.2.  Infants

14.7.2.2.3.  Adults

14.7.2.3.  The UK Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.2.3.1.  Blood cultures tests

14.7.2.3.2.  ELISA Tests

14.7.2.3.3.  Lateral Flow Assay

14.7.2.3.4.  PCR Assay

14.7.2.3.5.  At home tests

14.7.2.3.6.  Spinal tap

14.7.2.3.7.  Imaging

14.7.2.3.8.  Others

14.7.2.4.  The UK Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.2.4.1.  Oral

14.7.2.4.2.  Intravenous

14.7.2.4.3.  Subcutaneous

14.7.2.5.  The UK Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.2.5.1.  Vaccines

14.7.2.5.2.  Medications

14.7.2.5.2.1. Antibiotics

14.7.2.5.2.2. Antifungals

14.7.2.5.2.3. Corticosteroids

14.7.2.5.2.4. Antivirals

14.7.2.5.2.5. IV fluids

14.7.2.5.2.6. Others

14.7.2.5.3.  Others

14.7.3. Spain

14.7.3.1.  Spain Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.3.1.1.  Bacterial meningitis

14.7.3.1.2.  Viral meningitis

14.7.3.1.3.  Chronic meningitis

14.7.3.1.4.  Acute meningitis

14.7.3.1.5.  Fungal meningitis

14.7.3.1.6.  Parasitic meningitis

14.7.3.1.7.  Primary Amebic Meningitis (PAM)

14.7.3.1.8.  Others

14.7.3.2.  Spain Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.3.2.1.  Newborns

14.7.3.2.2.  Infants

14.7.3.2.3.  Adults

14.7.3.3.  Spain Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.3.3.1.  Blood cultures tests

14.7.3.3.2.  ELISA Tests

14.7.3.3.3.  Lateral Flow Assay

14.7.3.3.4.  PCR Assay

14.7.3.3.5.  At home tests

14.7.3.3.6.  Spinal tap

14.7.3.3.7.  Imaging

14.7.3.3.8.  Others

14.7.3.4.  Spain Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.3.4.1.  Oral

14.7.3.4.2.  Intravenous

14.7.3.4.3.  Subcutaneous

14.7.3.5.  Spain Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.3.5.1.  Vaccines

14.7.3.5.2.  Medications

14.7.3.5.2.1. Antibiotics

14.7.3.5.2.2. Antifungals

14.7.3.5.2.3. Corticosteroids

14.7.3.5.2.4. Antivirals

14.7.3.5.2.5. IV fluids

14.7.3.5.2.6. Others

14.7.3.5.3.  Others

14.7.4. Germany

14.7.4.1.  Germany Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.4.1.1.  Bacterial meningitis

14.7.4.1.2.  Viral meningitis

14.7.4.1.3.  Chronic meningitis

14.7.4.1.4.  Acute meningitis

14.7.4.1.5.  Fungal meningitis

14.7.4.1.6.  Parasitic meningitis

14.7.4.1.7.  Primary Amebic Meningitis (PAM)

14.7.4.1.8.  Others

14.7.4.2.  Germany Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.4.2.1.  Newborns

14.7.4.2.2.  Infants

14.7.4.2.3.  Adults

14.7.4.3.  Germany Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.4.3.1.  Blood cultures tests

14.7.4.3.2.  ELISA Tests

14.7.4.3.3.  Lateral Flow Assay

14.7.4.3.4.  PCR Assay

14.7.4.3.5.  At home tests

14.7.4.3.6.  Spinal tap

14.7.4.3.7.  Imaging

14.7.4.3.8.  Others

14.7.4.4.  Germany Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.4.4.1.  Oral

14.7.4.4.2.  Intravenous

14.7.4.4.3.  Subcutaneous

14.7.4.5.  Germany Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.4.5.1.  Vaccines

14.7.4.5.2.  Medications

14.7.4.5.2.1. Antibiotics

14.7.4.5.2.2. Antifungals

14.7.4.5.2.3. Corticosteroids

14.7.4.5.2.4. Antivirals

14.7.4.5.2.5. IV fluids

14.7.4.5.2.6. Others

14.7.4.5.3.  Others

14.7.5. Italy

14.7.5.1.  Italy Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.5.1.1.  Bacterial meningitis

14.7.5.1.2.  Viral meningitis

14.7.5.1.3.  Chronic meningitis

14.7.5.1.4.  Acute meningitis

14.7.5.1.5.  Fungal meningitis

14.7.5.1.6.  Parasitic meningitis

14.7.5.1.7.  Primary Amebic Meningitis (PAM)

14.7.5.1.8.  Others

14.7.5.2.  Italy Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.5.2.1.  Newborns

14.7.5.2.2.  Infants

14.7.5.2.3.  Adults

14.7.5.3.  Italy Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.5.3.1.  Blood cultures tests

14.7.5.3.2.  ELISA Tests

14.7.5.3.3.  Lateral Flow Assay

14.7.5.3.4.  PCR Assay

14.7.5.3.5.  At home tests

14.7.5.3.6.  Spinal tap

14.7.5.3.7.  Imaging

14.7.5.3.8.  Others

14.7.5.4.  Italy Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.5.4.1.  Oral

14.7.5.4.2.  Intravenous

14.7.5.4.3.  Subcutaneous

14.7.5.5.  Italy Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.5.5.1.  Vaccines

14.7.5.5.2.  Medications

14.7.5.5.2.1. Antibiotics

14.7.5.5.2.2. Antifungals

14.7.5.5.2.3. Corticosteroids

14.7.5.5.2.4. Antivirals

14.7.5.5.2.5. IV fluids

14.7.5.5.2.6. Others

14.7.5.5.3.  Others

14.7.6. Nordic Countries

14.7.6.1.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.6.1.1.  Bacterial meningitis

14.7.6.1.2.  Viral meningitis

14.7.6.1.3.  Chronic meningitis

14.7.6.1.4.  Acute meningitis

14.7.6.1.5.  Fungal meningitis

14.7.6.1.6.  Parasitic meningitis

14.7.6.1.7.  Primary Amebic Meningitis (PAM)

14.7.6.1.8.  Others

14.7.6.2.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.6.2.1.  Newborns

14.7.6.2.2.  Infants

14.7.6.2.3.  Adults

14.7.6.3.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.6.3.1.  Blood cultures tests

14.7.6.3.2.  ELISA Tests

14.7.6.3.3.  Lateral Flow Assay

14.7.6.3.4.  PCR Assay

14.7.6.3.5.  At home tests

14.7.6.3.6.  Spinal tap

14.7.6.3.7.  Imaging

14.7.6.3.8.  Others

14.7.6.4.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.6.4.1.  Oral

14.7.6.4.2.  Intravenous

14.7.6.4.3.  Subcutaneous

14.7.6.5.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.6.5.1.  Vaccines

14.7.6.5.2.  Medications

14.7.6.5.2.1. Antibiotics

14.7.6.5.2.2. Antifungals

14.7.6.5.2.3. Corticosteroids

14.7.6.5.2.4. Antivirals

14.7.6.5.2.5. IV fluids

14.7.6.5.2.6. Others

14.7.6.5.3.  Others

14.7.6.6.  Nordic Countries Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

14.7.6.6.1.  Denmark

14.7.6.6.2.  Finland

14.7.6.6.3.  Iceland

14.7.6.6.4.  Sweden

14.7.6.6.5.  Norway

14.7.7. Benelux Union

14.7.7.1.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.7.1.1.  Bacterial meningitis

14.7.7.1.2.  Viral meningitis

14.7.7.1.3.  Chronic meningitis

14.7.7.1.4.  Acute meningitis

14.7.7.1.5.  Fungal meningitis

14.7.7.1.6.  Parasitic meningitis

14.7.7.1.7.  Primary Amebic Meningitis (PAM)

14.7.7.1.8.  Others

14.7.7.2.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.7.2.1.  Newborns

14.7.7.2.2.  Infants

14.7.7.2.3.  Adults

14.7.7.3.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.7.3.1.  Blood cultures tests

14.7.7.3.2.  ELISA Tests

14.7.7.3.3.  Lateral Flow Assay

14.7.7.3.4.  PCR Assay

14.7.7.3.5.  At home tests

14.7.7.3.6.  Spinal tap

14.7.7.3.7.  Imaging

14.7.7.3.8.  Others

14.7.7.4.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.7.4.1.  Oral

14.7.7.4.2.  Intravenous

14.7.7.4.3.  Subcutaneous

14.7.7.5.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.7.5.1.  Vaccines

14.7.7.5.2.  Medications

14.7.7.5.2.1. Antibiotics

14.7.7.5.2.2. Antifungals

14.7.7.5.2.3. Corticosteroids

14.7.7.5.2.4. Antivirals

14.7.7.5.2.5. IV fluids

14.7.7.5.2.6. Others

14.7.7.5.3.  Others

14.7.7.6.  Benelux Union Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

14.7.7.6.1.  Belgium

14.7.7.6.2.  The Netherlands

14.7.7.6.3.  Luxembourg

14.7.8. Rest of Europe

14.7.8.1.  Rest of Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

14.7.8.1.1.  Bacterial meningitis

14.7.8.1.2.  Viral meningitis

14.7.8.1.3.  Chronic meningitis

14.7.8.1.4.  Acute meningitis

14.7.8.1.5.  Fungal meningitis

14.7.8.1.6.  Parasitic meningitis

14.7.8.1.7.  Primary Amebic Meningitis (PAM)

14.7.8.1.8.  Others

14.7.8.2.  Rest of Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

14.7.8.2.1.  Newborns

14.7.8.2.2.  Infants

14.7.8.2.3.  Adults

14.7.8.3.  Rest of Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

14.7.8.3.1.  Blood cultures tests

14.7.8.3.2.  ELISA Tests

14.7.8.3.3.  Lateral Flow Assay

14.7.8.3.4.  PCR Assay

14.7.8.3.5.  At home tests

14.7.8.3.6.  Spinal tap

14.7.8.3.7.  Imaging

14.7.8.3.8.  Others

14.7.8.4.  Rest of Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.7.8.4.1.  Oral

14.7.8.4.2.  Intravenous

14.7.8.4.3.  Subcutaneous

14.7.8.5.  Rest of Europe Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

14.7.8.5.1.  Vaccines

14.7.8.5.2.  Medications

14.7.8.5.2.1. Antibiotics

14.7.8.5.2.2. Antifungals

14.7.8.5.2.3. Corticosteroids

14.7.8.5.2.4. Antivirals

14.7.8.5.2.5. IV fluids

14.7.8.5.2.6. Others

14.7.8.5.3.  Others

14.8. Key Segment for Channeling Investments

14.8.1. By Country

14.8.2. By Type

14.8.3. By Age Group

14.8.4. By Diagnosis Type

14.8.5. By Route of Administration

14.8.6. By Treatment Type

15. Asia Pacific Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

15.1. Overview

15.1.1. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

15.2. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.2.1. Bacterial meningitis

15.2.2. Viral meningitis

15.2.3. Chronic meningitis

15.2.4. Acute meningitis

15.2.5. Fungal meningitis

15.2.6. Parasitic meningitis

15.2.7. Primary Amebic Meningitis (PAM)

15.2.8. Others

15.3. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.3.1. Newborns

15.3.2. Infants

15.3.3. Adults

15.4. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.4.1. Blood cultures tests

15.4.2. ELISA Tests

15.4.3. Lateral Flow Assay

15.4.4. PCR Assay

15.4.5. At home tests

15.4.6. Spinal tap

15.4.7. Imaging

15.4.8. Others

15.5. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.5.1. Oral

15.5.2. Intravenous

15.5.3. Subcutaneous

15.6. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.6.1. Vaccines

15.6.2. Medications

15.6.2.1.  Antibiotics

15.6.2.2.  Antifungals

15.6.2.3.  Corticosteroids

15.6.2.4.  Antivirals

15.6.2.5.  IV fluids

15.6.2.6.  Others

15.6.3. Others

15.7. Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

15.7.1. China

15.7.1.1.  China Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.1.1.1.  Bacterial meningitis

15.7.1.1.2.  Viral meningitis

15.7.1.1.3.  Chronic meningitis

15.7.1.1.4.  Acute meningitis

15.7.1.1.5.  Fungal meningitis

15.7.1.1.6.  Parasitic meningitis

15.7.1.1.7.  Primary Amebic Meningitis (PAM)

15.7.1.1.8.  Others

15.7.1.2.  China Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.1.2.1.  Newborns

15.7.1.2.2.  Infants

15.7.1.2.3.  Adults

15.7.1.3.  China Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.1.3.1.  Blood cultures tests

15.7.1.3.2.  ELISA Tests

15.7.1.3.3.  Lateral Flow Assay

15.7.1.3.4.  PCR Assay

15.7.1.3.5.  At home tests

15.7.1.3.6.  Spinal tap

15.7.1.3.7.  Imaging

15.7.1.3.8.  Others

15.7.1.4.  China Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.1.4.1.  Oral

15.7.1.4.2.  Intravenous

15.7.1.4.3.  Subcutaneous

15.7.1.5.  China Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.1.5.1.  Vaccines

15.7.1.5.2.  Medications

15.7.1.5.2.1. Antibiotics

15.7.1.5.2.2. Antifungals

15.7.1.5.2.3. Corticosteroids

15.7.1.5.2.4. Antivirals

15.7.1.5.2.5. IV fluids

15.7.1.5.2.6. Others

15.7.1.5.3.  Others

15.7.2. Japan

15.7.2.1.  Japan Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.2.1.1.  Bacterial meningitis

15.7.2.1.2.  Viral meningitis

15.7.2.1.3.  Chronic meningitis

15.7.2.1.4.  Acute meningitis

15.7.2.1.5.  Fungal meningitis

15.7.2.1.6.  Parasitic meningitis

15.7.2.1.7.  Primary Amebic Meningitis (PAM)

15.7.2.1.8.  Others

15.7.2.2.  Japan Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.2.2.1.  Newborns

15.7.2.2.2.  Infants

15.7.2.2.3.  Adults

15.7.2.3.  Japan Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.2.3.1.  Blood cultures tests

15.7.2.3.2.  ELISA Tests

15.7.2.3.3.  Lateral Flow Assay

15.7.2.3.4.  PCR Assay

15.7.2.3.5.  At home tests

15.7.2.3.6.  Spinal tap

15.7.2.3.7.  Imaging

15.7.2.3.8.  Others

15.7.2.4.  Japan Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.2.4.1.  Oral

15.7.2.4.2.  Intravenous

15.7.2.4.3.  Subcutaneous

15.7.2.5.  Japan Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.2.5.1.  Vaccines

15.7.2.5.2.  Medications

15.7.2.5.2.1. Antibiotics

15.7.2.5.2.2. Antifungals

15.7.2.5.2.3. Corticosteroids

15.7.2.5.2.4. Antivirals

15.7.2.5.2.5. IV fluids

15.7.2.5.2.6. Others

15.7.2.5.3.  Others

15.7.3. India

15.7.3.1.  India Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.3.1.1.  Bacterial meningitis

15.7.3.1.2.  Viral meningitis

15.7.3.1.3.  Chronic meningitis

15.7.3.1.4.  Acute meningitis

15.7.3.1.5.  Fungal meningitis

15.7.3.1.6.  Parasitic meningitis

15.7.3.1.7.  Primary Amebic Meningitis (PAM)

15.7.3.1.8.  Others

15.7.3.2.  India Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.3.2.1.  Newborns

15.7.3.2.2.  Infants

15.7.3.2.3.  Adults

15.7.3.3.  India Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.3.3.1.  Blood cultures tests

15.7.3.3.2.  ELISA Tests

15.7.3.3.3.  Lateral Flow Assay

15.7.3.3.4.  PCR Assay

15.7.3.3.5.  At home tests

15.7.3.3.6.  Spinal tap

15.7.3.3.7.  Imaging

15.7.3.3.8.  Others

15.7.3.4.  India Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.3.4.1.  Oral

15.7.3.4.2.  Intravenous

15.7.3.4.3.  Subcutaneous

15.7.3.5.  India Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.3.5.1.  Vaccines

15.7.3.5.2.  Medications

15.7.3.5.2.1. Antibiotics

15.7.3.5.2.2. Antifungals

15.7.3.5.2.3. Corticosteroids

15.7.3.5.2.4. Antivirals

15.7.3.5.2.5. IV fluids

15.7.3.5.2.6. Others

15.7.3.5.3.  Others

15.7.4. New Zealand

15.7.4.1.  New Zealand Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.4.1.1.  Bacterial meningitis

15.7.4.1.2.  Viral meningitis

15.7.4.1.3.  Chronic meningitis

15.7.4.1.4.  Acute meningitis

15.7.4.1.5.  Fungal meningitis

15.7.4.1.6.  Parasitic meningitis

15.7.4.1.7.  Primary Amebic Meningitis (PAM)

15.7.4.1.8.  Others

15.7.4.2.  New Zealand Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.4.2.1.  Newborns

15.7.4.2.2.  Infants

15.7.4.2.3.  Adults

15.7.4.3.  New Zealand Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.4.3.1.  Blood cultures tests

15.7.4.3.2.  ELISA Tests

15.7.4.3.3.  Lateral Flow Assay

15.7.4.3.4.  PCR Assay

15.7.4.3.5.  At home tests

15.7.4.3.6.  Spinal tap

15.7.4.3.7.  Imaging

15.7.4.3.8.  Others

15.7.4.4.  New Zealand Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.4.4.1.  Oral

15.7.4.4.2.  Intravenous

15.7.4.4.3.  Subcutaneous

15.7.4.5.  New Zealand Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.4.5.1.  Vaccines

15.7.4.5.2.  Medications

15.7.4.5.2.1. Antibiotics

15.7.4.5.2.2. Antifungals

15.7.4.5.2.3. Corticosteroids

15.7.4.5.2.4. Antivirals

15.7.4.5.2.5. IV fluids

15.7.4.5.2.6. Others

15.7.4.5.3.  Others

15.7.5. Australia

15.7.5.1.  Australia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.5.1.1.  Bacterial meningitis

15.7.5.1.2.  Viral meningitis

15.7.5.1.3.  Chronic meningitis

15.7.5.1.4.  Acute meningitis

15.7.5.1.5.  Fungal meningitis

15.7.5.1.6.  Parasitic meningitis

15.7.5.1.7.  Primary Amebic Meningitis (PAM)

15.7.5.1.8.  Others

15.7.5.2.  Australia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.5.2.1.  Newborns

15.7.5.2.2.  Infants

15.7.5.2.3.  Adults

15.7.5.3.  Australia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.5.3.1.  Blood cultures tests

15.7.5.3.2.  ELISA Tests

15.7.5.3.3.  Lateral Flow Assay

15.7.5.3.4.  PCR Assay

15.7.5.3.5.  At home tests

15.7.5.3.6.  Spinal tap

15.7.5.3.7.  Imaging

15.7.5.3.8.  Others

15.7.5.4.  Australia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.5.4.1.  Oral

15.7.5.4.2.  Intravenous

15.7.5.4.3.  Subcutaneous

15.7.5.5.  Australia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.5.5.1.  Vaccines

15.7.5.5.2.  Medications

15.7.5.5.2.1. Antibiotics

15.7.5.5.2.2. Antifungals

15.7.5.5.2.3. Corticosteroids

15.7.5.5.2.4. Antivirals

15.7.5.5.2.5. IV fluids

15.7.5.5.2.6. Others

15.7.5.5.3.  Others

15.7.6. South Korea

15.7.6.1.  South Korea Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.6.1.1.  Bacterial meningitis

15.7.6.1.2.  Viral meningitis

15.7.6.1.3.  Chronic meningitis

15.7.6.1.4.  Acute meningitis

15.7.6.1.5.  Fungal meningitis

15.7.6.1.6.  Parasitic meningitis

15.7.6.1.7.  Primary Amebic Meningitis (PAM)

15.7.6.1.8.  Others

15.7.6.2.  South Korea Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.6.2.1.  Newborns

15.7.6.2.2.  Infants

15.7.6.2.3.  Adults

15.7.6.3.  South Korea Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.6.3.1.  Blood cultures tests

15.7.6.3.2.  ELISA Tests

15.7.6.3.3.  Lateral Flow Assay

15.7.6.3.4.  PCR Assay

15.7.6.3.5.  At home tests

15.7.6.3.6.  Spinal tap

15.7.6.3.7.  Imaging

15.7.6.3.8.  Others

15.7.6.4.  South Korea Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.6.4.1.  Oral

15.7.6.4.2.  Intravenous

15.7.6.4.3.  Subcutaneous

15.7.6.5.  South Korea Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.6.5.1.  Vaccines

15.7.6.5.2.  Medications

15.7.6.5.2.1. Antibiotics

15.7.6.5.2.2. Antifungals

15.7.6.5.2.3. Corticosteroids

15.7.6.5.2.4. Antivirals

15.7.6.5.2.5. IV fluids

15.7.6.5.2.6. Others

15.7.6.5.3.  Others

15.7.7. Southeast Asia

15.7.7.1.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.7.1.1.  Bacterial meningitis

15.7.7.1.2.  Viral meningitis

15.7.7.1.3.  Chronic meningitis

15.7.7.1.4.  Acute meningitis

15.7.7.1.5.  Fungal meningitis

15.7.7.1.6.  Parasitic meningitis

15.7.7.1.7.  Primary Amebic Meningitis (PAM)

15.7.7.1.8.  Others

15.7.7.2.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.7.2.1.  Newborns

15.7.7.2.2.  Infants

15.7.7.2.3.  Adults

15.7.7.3.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.7.3.1.  Blood cultures tests

15.7.7.3.2.  ELISA Tests

15.7.7.3.3.  Lateral Flow Assay

15.7.7.3.4.  PCR Assay

15.7.7.3.5.  At home tests

15.7.7.3.6.  Spinal tap

15.7.7.3.7.  Imaging

15.7.7.3.8.  Others

15.7.7.4.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.7.4.1.  Oral

15.7.7.4.2.  Intravenous

15.7.7.4.3.  Subcutaneous

15.7.7.5.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.7.5.1.  Vaccines

15.7.7.5.2.  Medications

15.7.7.5.2.1. Antibiotics

15.7.7.5.2.2. Antifungals

15.7.7.5.2.3. Corticosteroids

15.7.7.5.2.4. Antivirals

15.7.7.5.2.5. IV fluids

15.7.7.5.2.6. Others

15.7.7.5.3.  Others

15.7.7.6.  Southeast Asia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

15.7.7.6.1.  Indonesia

15.7.7.6.2.  Thailand

15.7.7.6.3.  Malaysia

15.7.7.6.4.  Singapore

15.7.7.6.5.  Rest of Southeast Asia

15.7.8. Rest of Asia Pacific

15.7.8.1.  Rest of Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

15.7.8.1.1.  Bacterial meningitis

15.7.8.1.2.  Viral meningitis

15.7.8.1.3.  Chronic meningitis

15.7.8.1.4.  Acute meningitis

15.7.8.1.5.  Fungal meningitis

15.7.8.1.6.  Parasitic meningitis

15.7.8.1.7.  Primary Amebic Meningitis (PAM)

15.7.8.1.8.  Others

15.7.8.2.  Rest of Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

15.7.8.2.1.  Newborns

15.7.8.2.2.  Infants

15.7.8.2.3.  Adults

15.7.8.3.  Rest of Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

15.7.8.3.1.  Blood cultures tests

15.7.8.3.2.  ELISA Tests

15.7.8.3.3.  Lateral Flow Assay

15.7.8.3.4.  PCR Assay

15.7.8.3.5.  At home tests

15.7.8.3.6.  Spinal tap

15.7.8.3.7.  Imaging

15.7.8.3.8.  Others

15.7.8.4.  Rest of Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.7.8.4.1.  Oral

15.7.8.4.2.  Intravenous

15.7.8.4.3.  Subcutaneous

15.7.8.5.  Rest of Asia Pacific Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

15.7.8.5.1.  Vaccines

15.7.8.5.2.  Medications

15.7.8.5.2.1. Antibiotics

15.7.8.5.2.2. Antifungals

15.7.8.5.2.3. Corticosteroids

15.7.8.5.2.4. Antivirals

15.7.8.5.2.5. IV fluids

15.7.8.5.2.6. Others

15.7.8.5.3.  Others

15.8. Key Segment for Channeling Investments

15.8.1. By Country

15.8.2. By Type

15.8.3. By Age Group

15.8.4. By Diagnosis Type

15.8.5. By Route of Administration

15.8.6. By Treatment Type

16. Middle East and Africa Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

16.1. Overview

16.1.1. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

16.2. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.2.1. Bacterial meningitis

16.2.2. Viral meningitis

16.2.3. Chronic meningitis

16.2.4. Acute meningitis

16.2.5. Fungal meningitis

16.2.6. Parasitic meningitis

16.2.7. Primary Amebic Meningitis (PAM)

16.2.8. Others

16.3. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.3.1. Newborns

16.3.2. Infants

16.3.3. Adults

16.4. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.4.1. Blood cultures tests

16.4.2. ELISA Tests

16.4.3. Lateral Flow Assay

16.4.4. PCR Assay

16.4.5. At home tests

16.4.6. Spinal tap

16.4.7. Imaging

16.4.8. Others

16.5. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.5.1. Oral

16.5.2. Intravenous

16.5.3. Subcutaneous

16.6. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.6.1. Vaccines

16.6.2. Medications

16.6.2.1.  Antibiotics

16.6.2.2.  Antifungals

16.6.2.3.  Corticosteroids

16.6.2.4.  Antivirals

16.6.2.5.  IV fluids

16.6.2.6.  Others

16.6.3. Others

16.7. Middle East and Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

16.7.1. Saudi Arabia

16.7.1.1.  Saudi Arabia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.1.1.1.  Bacterial meningitis

16.7.1.1.2.  Viral meningitis

16.7.1.1.3.  Chronic meningitis

16.7.1.1.4.  Acute meningitis

16.7.1.1.5.  Fungal meningitis

16.7.1.1.6.  Parasitic meningitis

16.7.1.1.7.  Primary Amebic Meningitis (PAM)

16.7.1.1.8.  Others

16.7.1.2.  Saudi Arabia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.1.2.1.  Newborns

16.7.1.2.2.  Infants

16.7.1.2.3.  Adults

16.7.1.3.  Saudi Arabia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.1.3.1.  Blood cultures tests

16.7.1.3.2.  ELISA Tests

16.7.1.3.3.  Lateral Flow Assay

16.7.1.3.4.  PCR Assay

16.7.1.3.5.  At home tests

16.7.1.3.6.  Spinal tap

16.7.1.3.7.  Imaging

16.7.1.3.8.  Others

16.7.1.4.  Saudi Arabia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.1.4.1.  Oral

16.7.1.4.2.  Intravenous

16.7.1.4.3.  Subcutaneous

16.7.1.5.  Saudi Arabia Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.1.5.1.  Vaccines

16.7.1.5.2.  Medications

16.7.1.5.2.1. Antibiotics

16.7.1.5.2.2. Antifungals

16.7.1.5.2.3. Corticosteroids

16.7.1.5.2.4. Antivirals

16.7.1.5.2.5. IV fluids

16.7.1.5.2.6. Others

16.7.1.5.3.  Others

16.7.2. UAE

16.7.2.1.  UAE Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.2.1.1.  Bacterial meningitis

16.7.2.1.2.  Viral meningitis

16.7.2.1.3.  Chronic meningitis

16.7.2.1.4.  Acute meningitis

16.7.2.1.5.  Fungal meningitis

16.7.2.1.6.  Parasitic meningitis

16.7.2.1.7.  Primary Amebic Meningitis (PAM)

16.7.2.1.8.  Others

16.7.2.2.  UAE Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.2.2.1.  Newborns

16.7.2.2.2.  Infants

16.7.2.2.3.  Adults

16.7.2.3.  UAE Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.2.3.1.  Blood cultures tests

16.7.2.3.2.  ELISA Tests

16.7.2.3.3.  Lateral Flow Assay

16.7.2.3.4.  PCR Assay

16.7.2.3.5.  At home tests

16.7.2.3.6.  Spinal tap

16.7.2.3.7.  Imaging

16.7.2.3.8.  Others

16.7.2.4.  UAE Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.2.4.1.  Oral

16.7.2.4.2.  Intravenous

16.7.2.4.3.  Subcutaneous

16.7.2.5.  UAE Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.2.5.1.  Vaccines

16.7.2.5.2.  Medications

16.7.2.5.2.1. Antibiotics

16.7.2.5.2.2. Antifungals

16.7.2.5.2.3. Corticosteroids

16.7.2.5.2.4. Antivirals

16.7.2.5.2.5. IV fluids

16.7.2.5.2.6. Others

16.7.2.5.3.  Others

16.7.3. Egypt

16.7.3.1.  Egypt Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.3.1.1.  Bacterial meningitis

16.7.3.1.2.  Viral meningitis

16.7.3.1.3.  Chronic meningitis

16.7.3.1.4.  Acute meningitis

16.7.3.1.5.  Fungal meningitis

16.7.3.1.6.  Parasitic meningitis

16.7.3.1.7.  Primary Amebic Meningitis (PAM)

16.7.3.1.8.  Others

16.7.3.2.  Egypt Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.3.2.1.  Newborns

16.7.3.2.2.  Infants

16.7.3.2.3.  Adults

16.7.3.3.  Egypt Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.3.3.1.  Blood cultures tests

16.7.3.3.2.  ELISA Tests

16.7.3.3.3.  Lateral Flow Assay

16.7.3.3.4.  PCR Assay

16.7.3.3.5.  At home tests

16.7.3.3.6.  Spinal tap

16.7.3.3.7.  Imaging

16.7.3.3.8.  Others

16.7.3.4.  Egypt Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.3.4.1.  Oral

16.7.3.4.2.  Intravenous

16.7.3.4.3.  Subcutaneous

16.7.3.5.  Egypt Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.3.5.1.  Vaccines

16.7.3.5.2.  Medications

16.7.3.5.2.1. Antibiotics

16.7.3.5.2.2. Antifungals

16.7.3.5.2.3. Corticosteroids

16.7.3.5.2.4. Antivirals

16.7.3.5.2.5. IV fluids

16.7.3.5.2.6. Others

16.7.3.5.3.  Others

16.7.4. Kuwait

16.7.4.1.  Kuwait Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.4.1.1.  Bacterial meningitis

16.7.4.1.2.  Viral meningitis

16.7.4.1.3.  Chronic meningitis

16.7.4.1.4.  Acute meningitis

16.7.4.1.5.  Fungal meningitis

16.7.4.1.6.  Parasitic meningitis

16.7.4.1.7.  Primary Amebic Meningitis (PAM)

16.7.4.1.8.  Others

16.7.4.2.  Kuwait Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.4.2.1.  Newborns

16.7.4.2.2.  Infants

16.7.4.2.3.  Adults

16.7.4.3.  Kuwait Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.4.3.1.  Blood cultures tests

16.7.4.3.2.  ELISA Tests

16.7.4.3.3.  Lateral Flow Assay

16.7.4.3.4.  PCR Assay

16.7.4.3.5.  At home tests

16.7.4.3.6.  Spinal tap

16.7.4.3.7.  Imaging

16.7.4.3.8.  Others

16.7.4.4.  Kuwait Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.4.4.1.  Oral

16.7.4.4.2.  Intravenous

16.7.4.4.3.  Subcutaneous

16.7.4.5.  Kuwait Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.4.5.1.  Vaccines

16.7.4.5.2.  Medications

16.7.4.5.2.1. Antibiotics

16.7.4.5.2.2. Antifungals

16.7.4.5.2.3. Corticosteroids

16.7.4.5.2.4. Antivirals

16.7.4.5.2.5. IV fluids

16.7.4.5.2.6. Others

16.7.4.5.3.  Others

16.7.5. South Africa

16.7.5.1.  South Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.5.1.1.  Bacterial meningitis

16.7.5.1.2.  Viral meningitis

16.7.5.1.3.  Chronic meningitis

16.7.5.1.4.  Acute meningitis

16.7.5.1.5.  Fungal meningitis

16.7.5.1.6.  Parasitic meningitis

16.7.5.1.7.  Primary Amebic Meningitis (PAM)

16.7.5.1.8.  Others

16.7.5.2.  South Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.5.2.1.  Newborns

16.7.5.2.2.  Infants

16.7.5.2.3.  Adults

16.7.5.3.  South Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.5.3.1.  Blood cultures tests

16.7.5.3.2.  ELISA Tests

16.7.5.3.3.  Lateral Flow Assay

16.7.5.3.4.  PCR Assay

16.7.5.3.5.  At home tests

16.7.5.3.6.  Spinal tap

16.7.5.3.7.  Imaging

16.7.5.3.8.  Others

16.7.5.4.  South Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.5.4.1.  Oral

16.7.5.4.2.  Intravenous

16.7.5.4.3.  Subcutaneous

16.7.5.5.  South Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.5.5.1.  Vaccines

16.7.5.5.2.  Medications

16.7.5.5.2.1. Antibiotics

16.7.5.5.2.2. Antifungals

16.7.5.5.2.3. Corticosteroids

16.7.5.5.2.4. Antivirals

16.7.5.5.2.5. IV fluids

16.7.5.5.2.6. Others

16.7.5.5.3.  Others

16.7.6. Rest of Middle East & Africa

16.7.6.1.  Rest of Middle East & Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

16.7.6.1.1.  Bacterial meningitis

16.7.6.1.2.  Viral meningitis

16.7.6.1.3.  Chronic meningitis

16.7.6.1.4.  Acute meningitis

16.7.6.1.5.  Fungal meningitis

16.7.6.1.6.  Parasitic meningitis

16.7.6.1.7.  Primary Amebic Meningitis (PAM)

16.7.6.1.8.  Others

16.7.6.2.  Rest of Middle East & Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

16.7.6.2.1.  Newborns

16.7.6.2.2.  Infants

16.7.6.2.3.  Adults

16.7.6.3.  Rest of Middle East & Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

16.7.6.3.1.  Blood cultures tests

16.7.6.3.2.  ELISA Tests

16.7.6.3.3.  Lateral Flow Assay

16.7.6.3.4.  PCR Assay

16.7.6.3.5.  At home tests

16.7.6.3.6.  Spinal tap

16.7.6.3.7.  Imaging

16.7.6.3.8.  Others

16.7.6.4.  Rest of Middle East & Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.7.6.4.1.  Oral

16.7.6.4.2.  Intravenous

16.7.6.4.3.  Subcutaneous

16.7.6.5.  Rest of Middle East & Africa Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

16.7.6.5.1.  Vaccines

16.7.6.5.2.  Medications

16.7.6.5.2.1. Antibiotics

16.7.6.5.2.2. Antifungals

16.7.6.5.2.3. Corticosteroids

16.7.6.5.2.4. Antivirals

16.7.6.5.2.5. IV fluids

16.7.6.5.2.6. Others

16.7.6.5.3.  Others

16.8. Key Segment for Channeling Investments

16.8.1. By Country

16.8.2. By Type

16.8.3. By Age Group

16.8.4. By Diagnosis Type

16.8.5. By Route of Administration

16.8.6. By Treatment Type

17. Latin America Meningitis Diagnosis and Treatment Market Analysis and Forecasts, 2022 - 2030

17.1. Overview

17.1.1. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn)

17.2. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

17.2.1. Bacterial meningitis

17.2.2. Viral meningitis

17.2.3. Chronic meningitis

17.2.4. Acute meningitis

17.2.5. Fungal meningitis

17.2.6. Parasitic meningitis

17.2.7. Primary Amebic Meningitis (PAM)

17.2.8. Others

17.3. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

17.3.1. Newborns

17.3.2. Infants

17.3.3. Adults

17.4. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

17.4.1. Blood cultures tests

17.4.2. ELISA Tests

17.4.3. Lateral Flow Assay

17.4.4. PCR Assay

17.4.5. At home tests

17.4.6. Spinal tap

17.4.7. Imaging

17.4.8. Others

17.5. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

17.5.1. Oral

17.5.2. Intravenous

17.5.3. Subcutaneous

17.6. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

17.6.1. Vaccines

17.6.2. Medications

17.6.2.1.  Antibiotics

17.6.2.2.  Antifungals

17.6.2.3.  Corticosteroids

17.6.2.4.  Antivirals

17.6.2.5.  IV fluids

17.6.2.6.  Others

17.6.3. Others

17.7. Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Country

17.7.1. Brazil

17.7.1.1.  Brazil Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

17.7.1.1.1.  Bacterial meningitis

17.7.1.1.2.  Viral meningitis

17.7.1.1.3.  Chronic meningitis

17.7.1.1.4.  Acute meningitis

17.7.1.1.5.  Fungal meningitis

17.7.1.1.6.  Parasitic meningitis

17.7.1.1.7.  Primary Amebic Meningitis (PAM)

17.7.1.1.8.  Others

17.7.1.2.  Brazil Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

17.7.1.2.1.  Newborns

17.7.1.2.2.  Infants

17.7.1.2.3.  Adults

17.7.1.3.  Brazil Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

17.7.1.3.1.  Blood cultures tests

17.7.1.3.2.  ELISA Tests

17.7.1.3.3.  Lateral Flow Assay

17.7.1.3.4.  PCR Assay

17.7.1.3.5.  At home tests

17.7.1.3.6.  Spinal tap

17.7.1.3.7.  Imaging

17.7.1.3.8.  Others

17.7.1.4.  Brazil Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

17.7.1.4.1.  Oral

17.7.1.4.2.  Intravenous

17.7.1.4.3.  Subcutaneous

17.7.1.5.  Brazil Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

17.7.1.5.1.  Vaccines

17.7.1.5.2.  Medications

17.7.1.5.2.1. Antibiotics

17.7.1.5.2.2. Antifungals

17.7.1.5.2.3. Corticosteroids

17.7.1.5.2.4. Antivirals

17.7.1.5.2.5. IV fluids

17.7.1.5.2.6. Others

17.7.1.5.3.  Others

17.7.2. Argentina

17.7.2.1.  Argentina Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

17.7.2.1.1.  Bacterial meningitis

17.7.2.1.2.  Viral meningitis

17.7.2.1.3.  Chronic meningitis

17.7.2.1.4.  Acute meningitis

17.7.2.1.5.  Fungal meningitis

17.7.2.1.6.  Parasitic meningitis

17.7.2.1.7.  Primary Amebic Meningitis (PAM)

17.7.2.1.8.  Others

17.7.2.2.  Argentina Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

17.7.2.2.1.  Newborns

17.7.2.2.2.  Infants

17.7.2.2.3.  Adults

17.7.2.3.  Argentina Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

17.7.2.3.1.  Blood cultures tests

17.7.2.3.2.  ELISA Tests

17.7.2.3.3.  Lateral Flow Assay

17.7.2.3.4.  PCR Assay

17.7.2.3.5.  At home tests

17.7.2.3.6.  Spinal tap

17.7.2.3.7.  Imaging

17.7.2.3.8.  Others

17.7.2.4.  Argentina Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

17.7.2.4.1.  Oral

17.7.2.4.2.  Intravenous

17.7.2.4.3.  Subcutaneous

17.7.2.5.  Argentina Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

17.7.2.5.1.  Vaccines

17.7.2.5.2.  Medications

17.7.2.5.2.1. Antibiotics

17.7.2.5.2.2. Antifungals

17.7.2.5.2.3. Corticosteroids

17.7.2.5.2.4. Antivirals

17.7.2.5.2.5. IV fluids

17.7.2.5.2.6. Others

17.7.2.5.3.  Others

17.7.3. Rest of Latin America

17.7.3.1.  Rest of Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Type

17.7.3.1.1.  Bacterial meningitis

17.7.3.1.2.  Viral meningitis

17.7.3.1.3.  Chronic meningitis

17.7.3.1.4.  Acute meningitis

17.7.3.1.5.  Fungal meningitis

17.7.3.1.6.  Parasitic meningitis

17.7.3.1.7.  Primary Amebic Meningitis (PAM)

17.7.3.1.8.  Others

17.7.3.2.  Rest of Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Age Group

17.7.3.2.1.  Newborns

17.7.3.2.2.  Infants

17.7.3.2.3.  Adults

17.7.3.3.  Rest of Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Diagnosis Type

17.7.3.3.1.  Blood cultures tests

17.7.3.3.2.  ELISA Tests

17.7.3.3.3.  Lateral Flow Assay

17.7.3.3.4.  PCR Assay

17.7.3.3.5.  At home tests

17.7.3.3.6.  Spinal tap

17.7.3.3.7.  Imaging

17.7.3.3.8.  Others

17.7.3.4.  Rest of Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration

17.7.3.4.1.  Oral

17.7.3.4.2.  Intravenous

17.7.3.4.3.  Subcutaneous

17.7.3.5.  Rest of Latin America Meningitis Diagnosis and Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment Type

17.7.3.5.1.  Vaccines

17.7.3.5.2.  Medications

17.7.3.5.2.1. Antibiotics

17.7.3.5.2.2. Antifungals

17.7.3.5.2.3. Corticosteroids

17.7.3.5.2.4. Antivirals

17.7.3.5.2.5. IV fluids

17.7.3.5.2.6. Others

17.7.3.5.3.  Others

17.8. Key Segment for Channeling Investments

17.8.1. By Country

17.8.2. By Type

17.8.3. By Age Group

17.8.4. By Diagnosis Type

17.8.5. By Route of Administration

17.8.6. By Treatment Type

18. Competitive Benchmarking

18.1. Brand Benchmarking

18.2. Market Share Analysis, 2021

18.3. Global Presence and Growth Strategies

18.3.1. Mergers and Acquisitions

18.3.2. Product Launches

18.3.3. Investments Trends

18.3.4. R&D Initiatives

19. Player Profiles

19.1. Aurobindo Pharma Limited

19.1.1. Company Details

19.1.2. Company Overview

19.1.3. Product Offerings

19.1.4. Key Developments

19.1.5. Financial Analysis

19.1.6. SWOT Analysis

19.1.7. Business Strategies

19.2. Bio-Rad Laboratories, Inc.

19.2.1. Company Details

19.2.2. Company Overview

19.2.3. Product Offerings

19.2.4. Key Developments

19.2.5. Financial Analysis

19.2.6. SWOT Analysis

19.2.7. Business Strategies

19.3. ELITechGroup

19.3.1. Company Details

19.3.2. Company Overview

19.3.3. Product Offerings

19.3.4. Key Developments

19.3.5. Financial Analysis

19.3.6. SWOT Analysis

19.3.7. Business Strategies

19.4. F. Hoffman-La Roche Ltd

19.4.1. Company Details

19.4.2. Company Overview

19.4.3. Product Offerings

19.4.4. Key Developments

19.4.5. Financial Analysis

19.4.6. SWOT Analysis

19.4.7. Business Strategies

19.5. Fresensius Kabi India Pvt. Ltd

19.5.1. Company Details

19.5.2. Company Overview

19.5.3. Product Offerings

19.5.4. Key Developments

19.5.5. Financial Analysis

19.5.6. SWOT Analysis

19.5.7. Business Strategies

19.6. GSK plc

19.6.1. Company Details

19.6.2. Company Overview

19.6.3. Product Offerings

19.6.4. Key Developments

19.6.5. Financial Analysis

19.6.6. SWOT Analysis

19.6.7. Business Strategies

19.7. Pfizer Inc

19.7.1. Company Details

19.7.2. Company Overview

19.7.3. Product Offerings

19.7.4. Key Developments

19.7.5. Financial Analysis

19.7.6. SWOT Analysis

19.7.7. Business Strategies

19.8. Sanofi

19.8.1. Company Details

19.8.2. Company Overview

19.8.3. Product Offerings

19.8.4. Key Developments

19.8.5. Financial Analysis

19.8.6. SWOT Analysis

19.8.7. Business Strategies

19.9. Seegene Inc.

19.9.1. Company Details

19.9.2. Company Overview

19.9.3. Product Offerings

19.9.4. Key Developments

19.9.5. Financial Analysis

19.9.6. SWOT Analysis

19.9.7. Business Strategies

19.10. Serum Institute of India Pvt. Ltd

19.10.1. Company Details

19.10.2. Company Overview

19.10.3. Product Offerings

19.10.4. Key Developments

19.10.5. Financial Analysis

19.10.6. SWOT Analysis

19.10.7. Business Strategies

19.11. Thermo Fisher Scientific Inc.

19.11.1. Company Details

19.11.2. Company Overview

19.11.3. Product Offerings

19.11.4. Key Developments

19.11.5. Financial Analysis

19.11.6. SWOT Analysis

19.11.7. Business Strategies

19.12. Xellia Pharmaceuticals

19.12.1. Company Details

19.12.2. Company Overview

19.12.3. Product Offerings

19.12.4. Key Developments

19.12.5. Financial Analysis

19.12.6. SWOT Analysis

19.12.7. Business Strategies

19.13. Other Market Participants

20. Key Findings

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com